TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYR

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Rosen Law Firm
ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYR

Rosen Law Firm is investigating potential securities claims for aTyr Pharma investors who purchased stock between January 16 and September 12, 2025, alleging false statements about drug Efzofitimod's efficacy.

Insights
XLK   positive

High historical returns with 22.8% average annual gains over past decade, diverse technology sector exposure


ATYR   negative

Lawsuit alleges company disseminated false and misleading statements about drug efficacy, potentially causing investor damages